- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer (NSCLC)
- Meeting Date: July 2023
- Public Summary Document (PSD) July 2023 PBAC Meeting - (PDF 910KB)
- Public Summary Document (PSD) July 2023 PBAC Meeting - (Word 503KB)
Selpercatinib – July 2023
Selpercatinib: Capsule 40 mg, Capsule 80 mg; Retevmo® - July 2023
Last updated
10 November 2023